AstraZeneca’s PARP Inhibitor Lynparza Gets Approval in Japan

AstraZeneca AZN and partner Merck MRK announced that the Japanese Ministry of Health, Labour and Welfare has granted approval to its PARP inhibitor, Lynparza, as a maintenance therapy for relapsed ovarian cancer, irrespective of BRCA mutation status in patients who have responded to their last platinum-based chemotherapy.

• Source: finance.yahoo
• 677
• January 26, 2018